Radiation sensitization of human cervical cancer by proteasome inhibitor Velcade (Bortezomib)

被引：0
|
作者：
Kamer, S.
Ren, Q.
Sui, Y. P.
Kari, C.
Rodeck, U.
Dicker, A. P.
机构：
[1] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2334
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [1] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Serra Kamer
    Qing Ren
    Adam P. Dicker
    [J]. Archives of Gynecology and Obstetrics, 2009, 279 : 41 - 46
  • [2] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Kamer, Serra
    Ren, Qing
    Dicker, Adam P.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 279 (01) : 41 - 46
  • [3] The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer
    Thaler, Sonja
    Thiede, Gitta
    Hengstler, Jan G.
    Schad, Arno
    Schmidt, Marcus
    Sleeman, Jonathan P.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (03) : 686 - 697
  • [4] Pharmacokinetics of the proteasome inhibitor bortezomib (VELCADE™) in male cynomolgus monkeys.
    Nix, D
    Milton, M
    Pligavko, C
    Nagaraja, N
    Huang, R
    Miwa, G
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6263S - 6263S
  • [5] Pharmacokinetics and tissue distribution of the proteasome inhibitor bortezomib (VELCADE™) in rat and monkey
    Nix, D
    Press, R
    Wehrman, T
    Schenkein, DP
    [J]. BLOOD, 2002, 100 (11) : 224B - 224B
  • [6] Proteasome inhibitor bortezomib (Velcade™) and trastuzumab in HER-2 overexpressing breast cancer cell lines
    Laes, JF
    Cardoso, F
    Durbecq, V
    Lagneaux, L
    Hennuy, B
    Lallemand, F
    Gonze, I
    Di Leo, A
    Kern, F
    Ross, J
    Piccart, MJ
    Sotiriou, C
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S89 - S89
  • [7] Metabolism of the peptide boronic acid proteasome inhibitor bortezomib (VELCADE™) in multiple species
    LaButti, J
    Pekol, T
    Wang, RH
    Hsieh, F
    Daniels, JS
    Nix, D
    Gan, LS
    Miwa, G
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 41 - 41
  • [8] Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells
    Goktas, Serdar
    Baran, Yusuf
    Ural, Ali U.
    Yazici, Sertac
    Aydur, Emin
    Basal, Seref
    Avcu, Ferit
    Pekel, Aysel
    Dirican, Bahar
    Beyzadeoglu, Murat
    [J]. UROLOGY, 2010, 75 (04) : 793 - 798
  • [9] PROTEASOME INHIBITOR BORTEZOMIB INCREASES RADIATION SENSITIVITY IN ANDROGEN INDEPENDENT HUMAN PROSTATE CANCER CELLS
    Goktas, Serdar
    Ural, Ali U.
    Baran, Yusuf
    Yazici, Sertac
    Aydur, Emin
    Avcu, Ferit
    Pekel, Aysel
    Dirican, Bahar
    Beyzadeoglu, Murat
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 98 - 98
  • [10] The effect of proteasome inhibitor with Bortezomib (Velcade™) in B-cell lymphoma cell lines
    Strauss, SJ
    Lui, W
    Schenkein, D
    Shringarpure, R
    Anderson, K
    Lister, TA
    Joel, SP
    [J]. BLOOD, 2003, 102 (11) : 903A - 903A
12345